Accelerate Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference on August 13, 2015
TUCSON, Ariz., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 13th at 8:00AM ET.
A live webcast of the presentation will be posted from the investor portal of the Accelerate Diagnostics web site at http://ir.axdx.com/. An audio recording of the presentation will also be made available at this link shortly after the conclusion of the presentation.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. For more information, visit: www.acceleratediagnostics.com.
This press release contains words such as "expects," "shall," "will," "believes" and other similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company's current beliefs, known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company's results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. For a full discussion of the Company's risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in Item 1A in the Company's Transition Report on Form 10-KT, filed with the SEC on March 20, 2013. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
CONTACT: Media Contact:
Matt RussellRussell Public Communications
Jamien JonesBlueprint Life Science Group
415.375.3340 Ext. 103
Source: Accelerate Diagnostics, Inc.
News Provided by Acquire Media